Attis Industries Inc. (ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced that it closed the acquisition of Quality Rx Returns LLC (“Quality Rx”), a full service provider of pharmaceutical reverse logistic solutions, serving pharmacies, hospitals, and healthcare providers nationwide. Attis currently offers blood and toxicology panel, molecular diagnostic, and pharmacogenetic testing services for over 200 physician clinics, long-term care facilities, hospitals, and laboratories located from California to Florida. Attis plans to grow the Quality Rx business through its existing robust sales infrastructure, including its recently announced partnership with a new nationwide representative group.

“The February 2018 financing served its purpose at a critical time, but it included provisions that put the Company at risk of substantial dilution and restricted its ability to obtain financing, including at higher valuations,” stated, Jeff Cosman, Chief Executive Officer of Attis Industries.

Mr. Dunn, an attorney by trade who has worked for the Company since September of last year, has broad experience leading teams in sales organizations. As an attorney, Mr. Dunn represented both private and public-sector entities across a wide spectrum of issues. Mr. Dunn also spent a significant amount of time working directly for a multi-national Fortune 500 company in the medical device industry.

Attis Industries Inc. (ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced the execution of a letter of intent with Jordan Forest Products, LLC (“Jordan”) to provide raw material feedstock procurement services for its recently announced biorefinery in Barnesville, Georgia. Jordan is a division of Jordan Lumber & Supply Inc., one of the largest privately owned lumber companies in the U.S.

The Company’s Barnesville facility will generate roughly $35 million in annual revenue and contribute 40 direct green collar jobs to the local economy, with plans to increase to over 100 jobs within two years.

Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced that it has signed on a significant number of new accounts for commercial blood testing for its existing laboratory and laboratory partners. In recent weeks, the Company has added multiple new clinics in the Dallas, Memphis, and Phoenix markets, corresponding to at least 1,300 and 1,500 blood tests per month per clinic. “We continue to grow our business by providing top flight service to our customers and their patients,” said Jeff Cosman, the Company’s Chief Executive Officer.

Although the increase is welcomed by many in the industry, it remains far short of the original 2007 Renewable Fuel Standard that called for 13 billion gallons of advanced biofuels for 2019 and 21 billion gallons of advanced biofuel by 2022. The EPA has the authority to reduce the original mandate should it find that technology isn’t available for effective production of such amounts from known biomass resources.

The transaction was completed as part of the Company’s recent acquisition of an 80% stake in FLUX Carbon LLC (“JVCo”), and includes a license to use Noveda’s technologies. Noveda is leading the integration of emerging concepts like blockchain, artificial intelligence, and machine learning to streamline resource management, while helping to decrease consumption, optimize performance, and reduce carbon footprints for customers and users world-wide.

New Group Should Drive Significant Sample Volume. MILTON, GA, June 04, 2018-- Attis Industries, Inc., an integrated technology and innovations holding company, today announced that it has entered into ...

Plastic grocery bags are lightweight, strong, and extremely convenient for shoppers. “Numerous international governments have imposed initiatives to rid their jurisdictions of single-use bags in an effort to preserve natural resources and avoid irreparable harm to the environment,” said Jeff Cosman, Chief Executive Officer of Attis Industries.

It can be expected to initially contribute about $2 million to $3 million per year to the Company’s earnings. The joint venture also holds various investments in early-stage technology development companies, and the rights to many proprietary, patented, and patent-pending technologies, including (i) methods for real-time data acquisition, verification, and analytics in renewable energy applications, (ii) methods of using blockchain to manage commodity risk in emerging carbon and agricultural markets, (iii) low temperature catalysis of carbon dioxide into renewable fuels, (iv) power production from low temperature thermal emissions, and (v) methods to increase the efficiency and profitability of corn ethanol production facilities by intercepting and processing corn ethanol coproducts into value-added renewable offsets for fossil fuel-derived products.

Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced its execution and closing on a series of transactions effective May 25, 2018, including the acquisition by the Company’s subsidiary of a 49% stake in Genarex FD LLC (“Genarex”), and the restructuring of the Company’s November 2017 acquisition of Advanced Lignin Biocomposites LLC (“ALB”) to reduce the associated expense and liabilities by about 50%, or by about $1,350,000. Genarex is a technology development company focused on refining low-cost renewable feedstocks into functional biofillers for use in value-added plastics applications, with an emphasis on converting corn ethanol coproducts due to the large volumes, low costs as compared to conventional feedstocks, and high post-conversion values.

After looking at Attis Industries Inc’s (NASDAQ:ATIS) latest earnings announcement (31 March 2018), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

Bioplastics made from biomass can be used as renewable offsets for fossil fuel-derived feedstocks in manufacturing products for use in the same applications as traditional plastics. The global bioplastics market is one of the fastest growing sectors of the plastics industry, with a forecasted annual growth of 20-30%.

, May 22, 2018 (GLOBE NEWSWIRE) -- Attis Industries, Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced its approval of its lead sites for acquisition and construction of its planned biorefining facilities. Attis has accumulated a portfolio of patented and patent-pending technologies, all with a view towards building a nation-wide network of advanced new biorefineries designed to convert biomass into renewable alternatives for petroleum-derived fuels, plastics, and other products at far greater efficiencies as compared to conventional processes.

Attis Industries, Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), an integrated technology and innovations holding company, today announced that it is nearing completion of a new blood and toxicology laboratory in Tulsa, Oklahoma. Attis will operate the 1,800 square foot laboratory, which will be dedicated to running samples reimbursed by Medicare or individual state Medicaid programs only (“federal lab”).